The largest manager of U.S. prescription-drug benefits is taking sides in a fight between new hepatitis C treatments that cost close to $100,000 per patient..  Express Scripts Holding Co. will make an AbbVie Inc. drug the exclusive option for patients with the most common form of hepatitis C. The move will help the drug maker take market share from Gilead Sciences Inc., which makes the blockbuster Sovaldi, but is likely to be controversial for limiting doctors’ and patients’ treatment choices. 